Form 4: Phreesia Director Edward Cahill Acquires 400 Shares of Common Stock

Director Edward Cahill acquired 400 shares of Phreesia, Inc. common stock at $24.95 per share on July 31, 2024, increasing his direct holdings to 46,486 shares.

Summary

• On July 31, 2024, Edward Cahill, a director of Phreesia, Inc., acquired 400 shares of common stock at a price of $24.95 per share.
• The acquisition was made through the receipt of deferred stock units (DSUs) in lieu of an annual cash retainer, as part of Phreesia's Non-Employee Director Deferred Compensation Program.
• Following the transaction, Cahill directly owns 46,486 shares of Phreesia, Inc. common stock.
• The DSUs will be settled in common stock either 90 days after Cahill ceases to be a director or five years from the grant date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director is increasing their stake in the company, signaling confidence. However, it's a small transaction related to compensation, so the impact is limited.

Positives

• Director's acquisition of shares demonstrates confidence in the company.
• The Non-Employee Director Deferred Compensation Program aligns director interests with shareholder value.

Future Outlook

The DSUs will be settled in common stock either 90 days after Cahill ceases to be a director or five years from the grant date.

Industry Context

Directors acquiring company stock is generally viewed positively, as it aligns their interests with those of shareholders. This is a common practice among publicly traded companies to incentivize board members.

Comparison to Industry Standards

• Director compensation programs involving stock grants or options are common across the technology and healthcare industries, aiming to align director incentives with long-term shareholder value.
• Companies like Veeva Systems and Cerner (now Oracle Health) also utilize similar equity-based compensation for their board members.
• The specific terms of Phreesia's Non-Employee Director Deferred Compensation Program, such as the vesting schedule and settlement conditions, would need to be compared against industry benchmarks to assess its competitiveness and effectiveness.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders as it signals confidence from a director.

Key Dates